Loading…
LUCD
Lucid Diagnostics Inc.
NASDAQ· Healthcare· Medical Devices· CUSIP 54948X109
$0.99+0.75%Price as of Aug 29, 18:40 UTC · updated once a day, after the close
Key metrics
- Market cap
- $189.31M
- P/E
- —
- Forward P/E
- —
- P/B
- 17.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.41
- ROE
- -556.27%
- Profit margin
- 0.00%
- Revenue growth
- +26.70%
- Beta
- 1.08
- 52-week high
- $1.63
- 52-week low
- $0.86
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -91.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.09 | $0.82 | $1.41 | $1.36 | $5.37 | |
| P/S | 41.0x | 41.0x | 17.1x | 28.0x | 156.5x | 402.0x |
| P/B | 8.7x | 17.6x | 13.8x | — | 2.6x | 3.7x |
| EPS | -$0.69 | -$1.05 | -$1.26 | -$1.55 | -$1.51 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CNXUConexeu Sciences Inc. | $7.07 | — | 20.6x | — | — | $189.18M |
| VRXAVeraxa Biotech AG - Post de-SPAC | $1.35 | — | 0.5x | — | -65.29% | $190.9M |
| AIRSAirsculpt Technologies, Inc. | $2.60 | — | 1.8x | — | -11.98% | $187.45M |
| ORGOOrganogenesis Holdings Inc. | $1.45 |
About the company
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
- 82
- New York, United States
Company description provided by Yahoo Finance.